PubRank

Barbara Carnemolla

Author PubWeight™ 29.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004 6.97
2 Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003 3.52
3 Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A 2004 1.95
4 Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002 1.53
5 Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012 1.44
6 Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003 1.29
7 Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 2002 1.12
8 PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 2005 1.11
9 Identification of a novel cell binding site of periostin involved in tumour growth. Eur J Cancer 2011 1.01
10 Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 2006 0.96
11 Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer 2010 0.89
12 A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. Eur J Cancer 2013 0.88
13 Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: identification of differentially expressed and MAR-binding proteins. Exp Cell Res 2008 0.87
14 Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan. Eur J Immunol 2007 0.86
15 A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B. Int J Cancer 2009 0.85
16 Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. Cell Oncol 2008 0.85
17 Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur J Immunol 2007 0.85
18 Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8. PLoS One 2010 0.84
19 Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications. Anticancer Res 2005 0.82
20 Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins. J Biol Chem 2009 0.80
21 Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report. BMC Biotechnol 2011 0.79
22 Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. Cancer Med 2013 0.76